Search results

574 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Social care guidelines Remove Social care guidelines filter

Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mastocytosis (systemic) - masitinib [ID781]

In development [GID-TA10019] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

Type

NICE guideline

Status

In development
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]

In development [GID-TA10171] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Peramivir for treating influenza [ID828]

In development [GID-TA10155] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

In development [GID-TA10177] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

In development [GID-TA10159] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenalidomide for untreated follicular lymphoma ID1245

In development [GID-TA10308] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - methylnaltrexone bromide [ID700]

In development [GID-TA10003] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]

In development [GID-TA10008] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

Type

NICE guideline

Status

In development
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

In development [GID-TA10236] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

Type

NICE guideline

Status

In development
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487

In development [GID-TA10437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

In development [GID-TA10151] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis - diacerein [ID332]

In development [GID-TAG250] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Type

Technology appraisal guidance

Status

In development
Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: 19 April 2021

Type

Technology appraisal guidance

Status

In development
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

Type

NICE guideline

Status

In development
Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Type

Technology appraisal guidance

Status

In development
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development